Hopp

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022
U.S. Securities and Exchange Commission, Vaccine, SAP, KfW, Biotechnology, Neurodegeneration, SEC, Gesellschaft mit beschränkter Haftung, Spanish mythology, Ownership, Nasdaq, DGAP, Supervisory board, DBH Deutsche Buch Handels GmbH & Co. KG, News, Therapy, Cancer, Hopp, CVAC, Kommanditgesellschaft, Securities Act of 1933, Federal republic, Investment, Security (finance), Property management, CureVac

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

DGAP-News: dievini Hopp BioTech Congratulates CureVac on Successful Nasdaq IPO

Retrieved on: 
Wednesday, August 19, 2020
States of Germany, CureVac, Dietmar Hopp, Computer companies, SAP, Companies, Hopp, CVac, Walldorf, dievini, CureVac

WALLDORF, Germany - 19 August 2020 - dievini Hopp BioTech holding GmbH & Co. KG (dievini) congratulates portfolio company CureVac N.V. (Nasdaq: CVAC), a pioneer in the development of mRNA-based drugs, on its recent IPO on the U.S. Nasdaq stock exchange, citing it as a true European biotech success story.

Key Points: 
  • WALLDORF, Germany - 19 August 2020 - dievini Hopp BioTech holding GmbH & Co. KG (dievini) congratulates portfolio company CureVac N.V. (Nasdaq: CVAC), a pioneer in the development of mRNA-based drugs, on its recent IPO on the U.S. Nasdaq stock exchange, citing it as a true European biotech success story.
  • dievini remains the largest shareholder in CureVac with just under 50% and has invested further EUR 100 million in the IPO.
  • Dietmar Hopp, co-founder of dievini, said: "CureVac was one of the first investments in our portfolio, and I am pleased to see how the company has developed over the years, culminating in the recent IPO.
  • dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies.

DGAP-News: German Federal Government invests 300 Million Euros in CureVac

Retrieved on: 
Monday, June 15, 2020
States of Germany, Companies, CureVac, Government of Germany, Dietmar Hopp, Walldorf, KfW, SAP SE, Hopp, Peter Altmaier, Dietmar, dievini, CureVac AG

- mRNA company CureVac retains complete operational and strategic independence; the Federal Government will not influence corporate policy decisions

Key Points: 
  • - mRNA company CureVac retains complete operational and strategic independence; the Federal Government will not influence corporate policy decisions
    BERLIN/WALLDORF, Germany - 15 June 2020 - The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.
  • Under the agreement, the KfW will hold a stake of around 23 percent in CureVac.
  • The German Federal government has decided to invest in this promising company because it expects that this will accelerate the development programs and provide the means for CureVac to harness the full potential of its technology.
  • CureVac is just one of the early and outstanding examples of visionary entrepreneurial biotech innovation from Germany.